Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




DNA Test Assesses Risk of Malignant Hyperthermia

By LabMedica International staff writers
Posted on 14 Nov 2011
A molecular test may make it much simpler to identify patients at risk of malignant hyperthermia (MH) a life-threatening complication of exposure to anesthetics. More...


The new technique, called high resolution melting (HRM) curve analysis, provides a sensitive and specific tool for the identification of genetic variants responsible for MH and a much simpler alternative to currently available tests.

At Skåne University Hospital Lund (Malmö, Sweden) scientists developed an approach to assessing the risk of MH by using a sample of DNA extracted from a blood sample. Fragments of DNA from the ryanodine receptor 1 (RYR1) gene are identified and gradually heated to assess the temperature at which the strands of DNA begin to unwind. Fragments with unusual, or aberrant melting profiles can undergo full gene sequencing to pinpoint specific variants potentially causing MH.

The scientists evaluated the HRM curve analysis approach in 16 MH susceptible patients. All had either experienced a life-threatening episode of MH themselves, had a close relative who had died of MH, or had undergone the muscle biopsy test for suspected abnormalities. A total of approximately 2,500 DNA fragments underwent HRM curve analysis. The test showed significantly aberrant melting profiles in 21% of the DNA fragments tested. Subsequent gene sequencing studies identified 131 variants known to cause MH, along with 17 known or suspected mutations. Overall, 13 of the 16 MH-susceptible patients had genetic abnormalities known or suspected of causing MH, which is a rate of 81%. The use of HRM curve analysis to look for MH-related mutations of the RYR1 gene would greatly reduce the need for in-depth gene sequencing studies, without sacrificing test sensitivity.

Malignant hyperthermia is a rare condition in which genetically susceptible people develop rapid increases in body temperature and muscle rigidity in response to certain anesthetics and other drugs. Once the condition is recognized, it can generally be avoided by substituting other anesthetics. However, susceptible patients generally go unrecognized until they or a family member experience an episode of MH. The study was published in the November 2011 edition of the journal Anesthesia & Analgesia.

Related Links:
Skåne University Hospital



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.